1 Unpopular Stock That Should Get More Attention and 2 We Question
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...
/Bristol-Myers%20Squibb%20Co_%20logo%20on%20phone%20by-%20Piotr%20Swat%20via%20Shutterstock.jpg)
Bristol-Myers Squibb is approaching its first-quarter earnings release this month, and Wall Street is forecasting a double-digit percentage fall in earnings.
Gilead Sciences ($GILD) said Tuesday it will acquire Germany-based Tubulis GmbH for up to $5 billion, including $3.15 billion upfront and up to $1.85 billion in milestone payments, as the company expands...
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
New survey, guided by patient advocacy input, seeks to elevate lived experience and community voice to better understand challenges in multiple myeloma care
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 ...
High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies